Claims for Patent: 9,717,695

Summary for Patent: 9,717,695

Title:	Constructs for diagnosing and treating inflammatory bowel diseases and colon cancer
Abstract:	The present invention features, inter alia, constructs for the delivery of therapeutic and diagnostic agents to a patient. The constructs can include a nanoparticle, a targeting agent that specifically binds a targeted tissue or cell, a therapeutic moiety, and a hydrogel. The constructs can be used in the treatment and diagnosis of bowel diseases, including inflammatory bowel disease (IBD) and colon cancer. In one embodiment, the therapeutic agent is a nucleic acid that mediates RNA inhibition (RNAi), and the invention is directed to treatments for IBD that combine the positive aspects of such agents {e.g., siRNAs) with the safety of a biodegradable polymeric delivery system to facilitate specific targeting of colonic tissues and cells. As the constructs can be formulated for oral administration, they are well tolerated and offer advantages with regard to patient compliance.
Inventor(s):	Merlin; Didier (Decatur, GA), Xiao; Bo (Decatur, GA), Laroui; Hamed (Decatur, GA)
Assignee:	Georgia State University Research Foundation, Inc. (Atlanta, GA)
Application Number:	14/401,957
Patent Claims:	1. A drug delivery vehicle, wherein the vehicle comprises a plurality of nanoparticles, a targeting agent that specifically binds a targeted cell or tissue, a therapeutic moiety, and a hydrogel, wherein the targeting agent and the therapeutic moiety are associated with a nanoparticle of the plurality, thereby forming a core; the targeting agent is grafted to the nanoparticle via maleimide-polyethyleneglycol-poly(lactic acid); the hydrogel is generally peripheral to the core; and the nanoparticles have a polydispersity index (PI) below 0.3. 2. The drug delivery vehicle of claim 1, wherein the nanoparticles have a diameter in the range of about 1-1,000 nm and/or the nanoparticles comprise a naturally occurring polymer or a synthetic polymer. 3. The drug delivery vehicle of claim 1, wherein the nanoparticles comprise a biodegradable polymer or a non-biodegradable polymer. 4. The drug delivery vehicle of claim 1, wherein the targeting agent comprises an antibody, a single chain antibody (scFv), an Fab fragment, an Fab' fragment, or an F(ab').sub.2 fragment. 5. The drug delivery vehicle of claim 1, wherein the targeting agent binds to a cell or tissue within the gastrointestinal tract, the cell or tissue being cancerous, or a macrophage or dendritic cell. 6. The drug delivery vehicle of claim 4, wherein the antibody, scFv, Fab fragment, Fab' fragment, or F(ab').sub.2 fragment specifically binds an extracellular matrix protein. 7. The drug delivery vehicle of claim 1, wherein the therapeutic agent is a polypeptide, a nucleic acid, a radioisotope, a metal suitable for photodynamic therapy, or a non-protein, non-nucleotide chemical compound. 8. The drug delivery vehicle of claim 7, wherein the nucleic acid mediates RNAi or the chemical compound is an anti-inflammatory agent. 9. The drug delivery vehicle of claim 1, wherein the hydrogel comprises alginic acid and/or chitosan. 10. The drug delivery vehicle of claim 1, wherein the therapeutic agent is associated with the nanoparticles by virtue of being dissolve or entrapped therein. 11. The drug delivery vehicle of claim 1, further comprising a detectable label or tag. 12. The drug delivery vehicle of claim 1, wherein the targeting agent is an antibody, scFv, Fab fragment, Fab' fragment, or F(ab').sub.2 fragment that specifically binds F4/80, the therapeutic agent inhibits the expression or activity of TNF.alpha., and the hydrogel comprises alginic acid and/or chitosan. 13. A method of treating a patient who is suffering from an inflammatory bowel disease or colon cancer, the method comprising administering to the patient the drug delivery vehicle of claim 1. 14. A kit comprising the drug delivery vehicle of claim 1 and instructions for use. 15. The drug delivery vehicle of claim 4, wherein the antibody is adalimumab, certolizumab pegol, efalizumab, golimumab, infliximab, or natalizumab; the scFv is an scFv of adalimumab, certolizumab pegol, golimumab, or infliximab; and the Fab, Fab', or F(ab')2 fragment is a target-binding fragment of adalimumab, certolizumab pegol, golimumab, or infliximab. 16. The method of claim 13, wherein: the nanoparticles have a diameter in the range of about 1-1,000 nm; and/or the nanoparticles comprise a naturally occurring polymer or a synthetic polymer; and/or the targeting agent comprises an antibody, a single chain antibody (scFv), an Fab fragment, an Fab' fragment, or an F(ab').sub.2 fragment; and/or the therapeutic agent is a polypeptide, a nucleic acid, a radioisotope, a metal suitable for photodynamic therapy, or a non-protein, non-nucleotide chemical compound; and/or the hydrogel comprises alginic acid and/or chitosan; and/or the therapeutic agent is associated with the nanoparticles by virtue of being dissolved or entrapped therein; and/or the drug delivery vehicle further comprises a detectable label or tag. 17. The method of claim 16, wherein the antibody, scFv, Fab fragment, Fab' fragment, or F(ab').sub.2 fragment specifically binds an extracellular matrix protein. 18. The method of claim 16, wherein the nucleic acid mediates RNAi or the chemical compound is an anti-inflammatory agent. 19. The method of claim 16, wherein the antibody is adalimumab, certolizumab pegol, efalizumab, golimumab, infliximab, or natalizumab; the scFv is an scFv of adalimumab, certolizumab pegol, golimumab, or infliximab; and the Fab, Fab', or F(ab')2fragment is a target-binding fragment of adalimumab, certolizumab pegol, golimumab, or infliximab. 20. The kit of claim 14, wherein: the nanoparticles have a diameter in the range of about 1-1,000 nm; and/or the nanoparticles comprise a naturally occurring polymer or a synthetic polymer; and/or the targeting agent comprises an antibody, a single chain antibody (scFv), an Fab fragment, an Fab' fragment, or an F(ab').sub.2 fragment; and/or the therapeutic agent is a polypeptide, a nucleic acid, a radioisotope, a metal suitable for photodynamic therapy, or a non-protein, non-nucleotide chemical compound; and/or the hydrogel comprises alginic acid and/or chitosan; and/or the therapeutic agent is associated with the nanoparticles by virtue of being dissolved or entrapped therein; and/or the drug delivery vehicle further comprises a detectable label or tag. 21. The kit of claim 20, wherein the antibody, scFv, Fab fragment, Fab' fragment, or F(ab').sub.2 fragment specifically binds an extracellular matrix protein. 22. The kit of claim 20, wherein the nucleic acid mediates RNAi or the chemical compound is an anti-inflammatory agent. 23. The kit of claim 20, wherein the antibody is adalimumab, certolizumab pegol, efalizumab, golimumab, infliximab, or natalizumab; the scFv is an scFv of adalimumab, certolizumab pegol, golimumab, or infliximab; and the Fab, Fab', or F(ab')2fragment is a target-binding fragment of adalimumab, certolizumab pegol, golimumab, or infliximab.

Details for Patent 9,717,695

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2032-05-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	12/31/2002		2032-05-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	02/21/2008		2032-05-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	04/24/2013		2032-05-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	09/23/2014		2032-05-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	11/23/2015		2032-05-18
Abbvie Inc.	HUMIRA	adalimumab	Injection	125057	03/09/2016		2032-05-18